A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer

Cancer

Volumn 113, Issue 9, 2008, Pages 2448-2456

  Yoshitomi, Hideyuki ^a,b   Togawa, Akira ^a,b   Kimura, Fumio ^a,b   Ito, Hiroshi ^a,b   Shimizu, Hiroaki ^a   Yoshidome, Hiroyuki ^a   Otsuka, Masayuki ^a   Kato, Atsushi ^a   Nozawa, Satoshi ^a   Furukawa, Katsunori ^a   Miyazaki, Masaru ^a,b,c  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c NONE   (Japan)

Author keywords

Adjuvant therapy; Gemcitabine; Pancreatic cancer; Uracil tegafur

Indexed keywords

GEMCITABINE; UFT;

ADJUVANT THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLUCOSE INTOLERANCE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADENOCARCINOMA, PAPILLARY; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE; TEGAFUR; URACIL;

EID: 55549116683     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23863     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;57:43-66.
2. The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2007. Available at: http://ganjoho. ncc.go.jp/public/statistics/ backnumber/2007_en.html Accessed on February 28, 2008
3. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
4. Imamura M, Doi R, Imaizumi T, et al. A randomized multicenter trial comparing resection and radiochemotherapy for respectable locally invasive pancreatic cancer. Surgery. 2004;136:1003-1011.
5. Japan Pancreas Society. Pancreatic cancer registry report 2007. Suizo. 2007;22:39.
6. Pedrazzoli S, DiCarlo V, Dionig R, et al. and the Lymphadenectomy Study Group. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. A multicenter, prospective randomized study. Ann Surg. 1998;228:508-517.
7. Yeo CY, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or eithout distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2. Ann Surg. 2002;236:355-368.
8. Farnell MB, Pearson RK, Sarr MG, et al. and the Pancreas Cancer Working Group. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in respectable pancreatic head adenocarcinoma. Surgery. 2005; 138:618-630.
9. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998;352:930-942.
10. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
11. Sakuramoto S, Sasako M, Yamaguchi T, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-1820.
12. Kalser MH, Ellenberg SS. Pancretic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903.
13. Bakkevold K, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of caterresults of a controlled, prospective randomized multicenter study. Eur J Can. 1993;29A:698-703.
14. Study Group of Surgical Adjuvant Therapy for Carcinoma of the Pancreas, Biliary Tract, Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685-1695.
15. Kosuge T, Kiuchi T, Mukai K, Kakizoe T for the Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP). A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006;36:159-165.
16. Klinkenbijl JHG, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC GITCCG. Ann Surg. 1999;230:776-784.
17. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
18. Stocken DD, Buchler MW, Dervenis C, et al on behalf of the Pancreatic Cancer Meta-analysis Group. Meta-analysis of randomized adjuvant trials for pancreatic cancer. Br J Cancer. 2005;92:1372-1381.
19. Burris HA III, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
20. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA. 2007; 297:267-277.
21. Fujii S, Kitano S, Irenaka K, Shirasak T. Effect of coadministration of uracil or cytosine on the anti-tumour activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann. 1979;70:209-214.
22. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000;60:6075-6079.
23. Seto Y, Yoh K, Asoh H, Yamamoto H, Semba H, Ishinose Y. A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer. Br J Cancer. 2002;86:1701-1704.
24. Ichinose Y, Seto T, Semba H, et al. UFT plus gemcitabine combination chemotherapy in patients with advanced nonsmall cell lung cancer: a multi-institutional phase II trial. Br J Cancer. 2005;93:770-773.
25. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212-2217.
26. Japan Pancreatic Society. Classification of Pancreatic Carcinoma. 2nd ed. Tokyo, Japan: Kanehara & Co. Ltd.; 2003.
27. Neoptoleomos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet. 2001; 358:1576-1585.
28. Feliu J, Mel R, Borrega P, et al. on behalf of the Oncopaz cooperative group, Spain. Phase II study of a fixed doserate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann Oncol. 2002; 13:1756-1762.
29. Lee J, Park JO, Kim WS, et al. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. Oncology. 2004;66:32-37.
30. Onoue M, Terada T, Okuda M, et al. Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer. Int J Clin Oncol. 2004;9:174-178.
31. Neoptolemos JP, Stocken DD, Dunn JA, et al. European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234:758-768.
32. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma. A population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74-85.
33. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/ examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2004;70:235-240.